Pharmaceutical technology assessment: Perspectives from payers

Journal of Managed Care Pharmacy

Volumn 18, Issue 3, 2012, Pages 256-264

  Leung, Musetta Y ^a   Halpern, Michael T ^a   West, Nathan D ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION MAKING; ECONOMICS; HUMAN; MEDICARE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PEER REVIEW; PHARMACEUTICAL TECHNOLOGY ASSESSMENT; QUALITATIVE ANALYSIS; QUALITY CONTROL PROCEDURES; SEMI STRUCTURED INTERVIEW; TELECONSULTATION;

EID: 84860741571     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2012.18.3.256     Document Type: Article

References (13)

1. Catlin A, Cowan C, Hartman M, Heffler S. National health spending in 2006: a year of change for prescription drugs. Health Aff (Millwood). 2008;27(1):14-29. Available at: http://content.healthaffairs.org/content/27/1/14.full.pdf+html. Accessed March 7, 2012.
2. Robinson JC. Insurers' strategies for managing the use and cost of biopharmaceuticals. Health Aff (Millwood). 2006;25(5):1205-17. Available at: http://content.healthaffairs.org/content/25/5/1205.full.pdf+html. Accessed March 7, 2012.
3. Giaquinta D. The changing timetable for the evaluation of new products for formulary consideration. Manag Care Interface. 2003;16(2):24-25,28.
4. Levinson W, Laupacis A. A call for fairness in formulary decisions. Arch Intern Med. 2006;166(1):16-18.
5. Fullerton DS, Atherly D, Sullivan SD. Showing outcomes and proving value brings success. Manag Care Interface. 2001;14(6):63-65,71.
6. Spooner JJ, Gandhi PK, Connelly SB. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan. J Manag Care Pharm. 2007;13(1):37-43. Available at: http://amcp.org/data/jmcp/37-43.pdf.
7. Langley PC. Formulary submission guidelines for Blue Cross and Blue Shield of Colorado and Nevada. Structure, application and manufacturer responsibilities. Pharmacoeconomics. 1999;16(3):211-24.
8. Garber AM. Evidence-based coverage policy. Health Aff (Millwood). 2001;20(5):62-82. Available at: http://content.healthaffairs.org/content/20/5/62.full.pdf. Accessed March 7, 2012.
9. Holtorf AP, Watkins JB, Mullins CD, Brixner D. Incorporating observational data into the formulary decision-making process-summary of a roundtable discussion. J Manag Care Pharm. 2008;14(3):302-08. Available at: http://www.amcp.org/data/jmcp/JMCPMaga_April08_302-308.pdf.
10. Bozzette SA, D'Amato R, Morton S, Harris K, Meili R, Taylor R. Pharmaceutical technology assessment for managed care: current practice and suggestions for improvement. RAND report prepared for Sanofi-Synthelabo Inc. August 2001. Available at: http://www.rand.org/pubs/monograph_reports/2005/MR1206.pdf. Accessed March 7, 2011.
11. Nichol MB, Knight TK, Epstein J, Honda DH, Tretiak R. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers. J Manag Care Pharm. 2007;13(4):360-71. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7568.
12. Suh D, Okpara IR, Agnese WB, Toscani M. Application of pharmacoeconomics to formulary decision making in managed care organizations. Am J Manag Care. 2002;8(2):161-69. Available at: http://www.ajmc.com/media/pdf/AJMC2002febSuh161_169.pdf. Accessed March 7, 2012.
13. Lyles A, Watkins JD. Manufacturer response to AMCP Format dossier requests. J Manag Care Pharm. 2007:13(3):290-91. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7564.